Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Video Gaming and eSports ETF (ESPO) vs Cassava Sciences Inc (FLNA) Price & Performance

VanEck Video Gaming and eSports ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

VanEck Video Gaming and eSports ETF vs Cassava Sciences Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.92 (market cap $248.06M), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: VanEck Video Gaming and eSports ETF is far larger — about 6.3× Cassava Sciences Inc's market cap, and VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Cassava Sciences Inc for 37 Days on average.

ESPOFLNA
Market Cap
$248.06M$39.40M
Volume
13,622759,018
Sector
Sector/ThematicHealth
52-Week High
$118.68$4.64
52-Week Low
$85.25$0.68
Typical Hold Time
66 Days37 Days
Enterprise Value
—-$43.28M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Video Gaming and eSports ETF

ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.

The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.

Cassava Sciences Inc

FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.

The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ESPO
0% Buy100% Sell
Avg holding period · 66 Days
FLNA
47% Buy53% Sell
Avg holding period · 37 Days

About VanEck Video Gaming and eSports ETF

ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.

Read more on ESPO →

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →